
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































identify  truly  the most  appropriate  partners.  Because  now  in  hindsight  I  am 
thinking  there  are  a  couple  of  partners  on  the  stakeholder  [committee]  that 

























































































































































































































































































































































importance. CBOs seem  inclined  to work on good  faith, not memorandums of 




























































































































































































“There  is a need  in education. You don’t know what you are getting  in.  If you have 


















“I’ll  give  you  one  example  of  how  this  hepatitis  could  be  perceived  or 
misinformed. Some people, I talk about the jaundice. When they see the liver or 





















































































































































































































































  Site X  Site Y  Total 




Number HBV education events  2  12  14 
Number HBV screening events  10  15  25 
Number people screened  645  1,061  1,706 
Number people educated  800  357  1,157 
Number vaccine clinics  24  20  44 






















































































































































































































































































they  are  completing  their  follow‐up  calls, while  still maintaining  a  friendly,  balanced 
relationship with these partners. We do need them to complete their calls and we want 



















































































































































































































there were a  lot of people  from  that event who were already protected against HBV, and  the project 



































































































“XX  is a Vietnamese‐owned pharmacy, and has bi‐lingual  staff members who  speak 5 
languages. Thus, it is a trusted community site, and has a strong local following in the API 
community. XX  is a new neighborhood  for us, and working with XX has allowed us  to 
successfully screen over 150 individuals. They promoted the event to all of their clients in 


































They were  able  to  block  of  4  days  in  April  and make  appointments  for  24  infected 
individuals. We  submitted  test  results  to  XX  for  infected  individuals,  XX  called  all  24 






their  scheduled  appointment.  This  can  be  a  successful  model  of  sustainability  for 













“Rolling  in  the  screening  event  with  vaccine  was  also  very  successful.  At  the  4/27 
screening  event, we  offered  the  vaccine  to  those who were  screened  at  XX  back  in 




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3 Community Coalition Action Theory




























Conditions that foster productive collaborations and coalitions. Coalitions must be dynamic and 
responsive to culture, racial, and ethnic diversity, and how people usually work together in a 
community, region, or state (Butterfoss, 2007). Contextual or environmental factors can enhance or 
inhibit collaboration and significantly impact a coalition throughout its development (Butterfoss & 
Kegler, 2009, Lasker, Weiss & Miller, 2001; Mattesich, Murray-Close & Monsey, 2001).  




Formation  Build community ownership
 Assess community needs & assets (e.g., by using MAPP tool)
 Develop commitment for vision, mission, goals & objectives
 Create viable organizational structure
 Recruit key organizational members
 Build leadership team
Maintenance  Retain member commitment & participation to achieve goals
 Obtain and share member resources
 Continue to assess community assets & needs
 Plan/implement effective PSEs
Institutionalization  Diversify & strengthen coalition’s financial base
 Ensure Community Home for ongoing efforts
 Plan for leadership succession


















































A p p e n d i x  C


fo L1~@ HEPATITIS B FOUNDATION ~(~ 3805 Old Easton Road Doylestown, PA 18902 
Phone: (215) 489-4900 
Email: info@hepb.org 
CAUSE FORA CURE 
www.hepb.org 
Approval Oat : Ot-! 1/3h J-. 
Hepatitis B Screening Form (Revised April 9, 2012) 
Screening ill: ______ _ 
Age: ___ _ 
Gender: 10 M 20 F 
1. Ethnicity: 10 Black 20 White 30 Hispanic 40 AsianlPacific Islander 
sO Native American/Alaska Native 60 Other: 
2. Highest level of education: 10 Less than high school 20 High school diploma 
30 Technical/vocational training 40 Some college 
sO College degree 60 Graduate degree 
Alternatively, if your native education system is different, how many years of school did you attend? _ 
3. How many people live with you now? ___ _ 
4. Are you currently living with anyone with Hepatitis B? 10 Yes 20 No 30 Don't Know 
5 . Country of birth: ______ _ 
6. Year arrived in US: 
----
7. Mother's country of birth: ___ _ 8. Father' s country of birth: ____ _ 
9. If you are woman, are you currently pregnant or do you suspect that you are pregnant? 
10 Yes 20 No 30 Don't know 
10. Is English your primary language? 





12. Do you have a regular doctor or health care provider? 1 0 Yes 2 0 No 
13. Have you seen a doctor within the past 12 months? 10 Yes 20 No 
14. Why are you here for testing? 
10 My doctor recommended I come in for testing 
20 My insurance won't cover testing and I want to be tested 
30 I think I might be infected with hepatitis B 
40 A family member or personal contact is infected with hepatitis B 
sO I saw/heard an ad for it 
60 My family member recommended I come in 
70 I was here or at an event and someone recruited me 
sO Other reason: 
---------------- -
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15. Have you ever been tested for hepatitis B before today or has a doctor ever told you that you had hepatitis B? 
10 Yes 20 No 30 Don't know 
If yes, what was the outcome of the test? 10 Positive 20 Negative 30 Don't know Approv lOt 
16. If you have never been tested for hepatitis B before, please list the reason(s) (please check all that apply): 
10 The cost of hepatitis B testing was more than I can afford 
20 I did not know where to get a test 
30 No doctor ever recommended that I get tested 
40 I am scared ofneedleslblood tests 
50 I did not think that I was at risk for hepatitis B 
60 I was scared to find out I have hepatitis B 
70 Other reason (please specify): ______ ______________ _ 
17. Were you ever given medicine to treat hepatitis B? 
10 Yes 20 No 30 Don't know 
18. Have you ever received vaccination or shots to protect you from hepatitis B? 
10 Yes 20 No 30 Don't know 
19. Do you have any family members with hepatitis B? 1 0 Yes 
If yes, who has hepatitis B? 10 Spouse 20 Mother 
50 Child 60 Cousin 
80 AuntlUncle 90 other: 
20 No 
30 Father 
30 Don't know 
40 Sibling 
70 Grandparent 
20. Do you have any family members with liver cancer? 10 Yes 20 No 30 Don't know 
If yes, who has liver cancer? 10 Spouse 20 Mother 30 Father 40 Sibling 
50 Child 60 Cousin 70 Grandparent 
80 AuntlUncle 90 other: 
20. At the end of this screening, if you test positive, do you intend on seeking treatment within 
the next 6 months? lO Y es 
20 I'd like to, but I cannot pay for treatment ifI'm positive 
30 No, I don't want to be treated right now for non-financial reasons 
Thank you for completing this form! 
CBO SUBCONTRACTOR INTERVIEW GUIDE  
Thank you for your time today. I’m ____ and I’m from RTI, a nonprofit research organization. I 
am conducting a series of these interviews for the Centers for Disease Control and Prevention 
(CDC), an agency of the U.S. Department of Health and Human Services.  
I’d like to talk about your experiences as a stakeholder for the CDC project to build capacity for 
screening, vaccination, and linkage to care for foreign-born persons at highest risk of hepatitis B. 
The reason we are having this interview is to hear your opinions about the project so that we can 
see what’s worked, what hasn’t, and what lessons have been learned over the past year. The CDC 
plans to use this information to develop national guidance for screening, vaccination, and linkage 
to care for foreign-born persons at risk for hepatitis B. Your insights and experiences are very 
important to this process, and your time today is appreciated.  
Before we begin, I want to review a few things:  
Your participation is voluntary.
Everything we discuss today will be kept private to the extent allowable by law. I will be audio
recording our conversation today and my colleague _________ will be taking notes as we talk. 
The recordings and notes will be used to help us write a summary report and will be kept in a 
secure location and then destroyed at the conclusion of the study. I want to stress that no names 
will be mentioned in the final report created from the focus groups; you will only be referred to by 
your role as CBO subcontractors.  
If at any time you are uncomfortable with the questions, you can choose not to answer. Just let
me know that you prefer not to answer if I should call on you. 
Most importantly, there are no right or wrong answers. I want to know your opinions.
Do you have any questions before we begin?
1 Program Development 
1. What were some of the reasons your organization decided to become involved in this project?
2. What were some of your initial concerns?
– Were they addressed? If so, how?
3. Walk me through the initial planning for this project:
– What steps did you go through?
– Who did you work with during the initial planning? (PROBE: outside organizations, specific
partners, get at why they were brought in) 
4. What were some of the challenges you faced when planning this project? How were they
overcome? (PROBE: internal to organization, external, resource-based) 
5. [Seattle only] What were your experiences working with [HBCW]/[HEP] to develop this project?
What worked well? What didn’t work well and why? 
2 Training and Technical Assistance 
1. What kind of training or technical assistance did you receive during the implementation period?
2. How helpful was the training and technical assistance you received? How could it have been
improved?  
3. What other types of training or technical assistance would you have liked to receive?
4. What kinds of training or TA would be essential for organizations wishing to implement a similar
program?  
3 Data Collection and Management 
1. What have been your experiences with data collection? What worked well? What didn’t work
well and why? 
2. What kinds of changes to data collection were made during the project period? To what extent
were these changes helpful? 
3. How have you used the data for monitoring and evaluation purposes?
4. After the project ends, do you intend to continue collecting these data? Why or why not?
5. What other data elements would you like to add going forward?
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6. [for Seattle only] Tell us about the data sharing process. What worked well? What didn’t work
well and why? How could it be improved? 
3.1 Stakeholder Committee 
1. How did you choose the members of your stakeholder committee? Walk me through how you
decided who to include and why you chose them.  
2. Describe for me the key activities of the stakeholder committee.
3. Did the stakeholder committee benefit the project? If so, in what ways?
– Was having a stakeholder committee necessary for the success of the project?
4. From your experiences on this project, what are some of the qualities of engaged stakeholders?
5. What were some of the challenges encountered by the stakeholder committee? How were the
challenges addressed? 
6. What were some of the challenges encountered by you in your role with the stakeholder
committee? How were the challenges addressed? 
7. How did you decide on the format and structure of the meetings?
8. In terms of the format and structure of the meetings, what worked well? What didn’t work well
and why? (PROBE: meeting frequency, subject matter, participation levels)  
9. How do you communicate with stakeholder committee members outside of the regular
meetings? (PROBE: mechanisms, frequency) 
10. How has the stakeholder committee changed over time?
11. Is there anything you wish was different about the stakeholder committee? If yes, what?
12. Do you have suggestions for other jurisdictions that might be working on developing a
stakeholder committee for a similar project? 
3.2 Sustainability 
1. What were your organization’s greatest successes during this project?
– To what or whom do you attribute these successes?
2. More globally, what were the project’s greatest successes? To what or whom do you attribute
these successes? 
3. What resources were critical to the program’s success? How were they critical?
4. What resources were lacking or missing altogether?
5. To what extent do you think the program is sustainable?
– What parts are most sustainable? Why?
– What parts are least sustainable? Why? How could you address the lack of sustainability?
6. What resources are critical to sustainability? How easily do you think it will be to put these into
place? What barriers might you encounter? 
7. [Seattle only] How do you envision working with [HBCW]/[HEP] in the future to continue this
work? What resources will be necessary to sustain your partnership? 
4 Conclusion 
1. If another CBO asked you for advice about starting up a similar program, what would you tell
them?  
2. Is there anything else you would like to say about any of the topics we’ve discussed or about
your experiences? 
I would like to thank you for your time and opinions today. Your feedback was very useful and will 
be very helpful. 
STAKEHOLDER FOCUS GROUP GUIDE 
Thank you for your time today. I’m ____ and I’m from RTI, a nonprofit research organization. I 
am conducting a series of these interviews for the Centers for Disease Control and Prevention 
(CDC), an agency of the U.S. Department of Health and Human Services.  
We’re here today to talk about your experiences as stakeholders for the CDC project to build 
capacity for screening, vaccination, and linkage to care for foreign-born persons at highest risk of 
hepatitis B. The reason we are having this focus group is to hear your opinions about the project 
so that we can see what’s worked, what hasn’t, and what lessons have been learned over the past 
year. The CDC plans to use this information to develop national guidance for screening, 
vaccination, and linkage to care for foreign-born persons at risk for hepatitis B. Your insights and 
experiences are very important to this process, and your time today is appreciated. 
Before we begin, I want to review a few things:  
Your participation is voluntary.
Everything we discuss today will be kept private to the extent allowable by law. I will be audio
recording our conversation today and my colleague _________ will be taking notes as we talk. 
The recordings and notes will be used to help us write a summary report and will be kept in a 
secure location and then destroyed at the conclusion of the study. I want to stress that no names 
will be mentioned in the final report created from the focus groups; you will only be referred to by 
your role as stakeholders.  
If at any time you are uncomfortable with the questions, you can choose not to answer. Just let
me know that you prefer not to answer if I should call on you. 
Most importantly, there are no right or wrong answers. I want to know your opinions.
Do you have any questions before we begin?
I’d like to start by having each of you introduce yourselves. If you could please let me know your 
name, your organization, and your role there.  
1 Program Development 
1. By a show of hands, how many of your organizations were involved in hepatitis B work before
this project? 
2. How did your organization become involved in this current project?
3. What were some of the factors you weighed as you considered becoming involved with this
project?  
4. By a show of hands, how many of your organizations have worked with [CBO subcontractor(s)]
before this project?  
– If yes, how long have you worked with [CBO subcontractor(s)]?
– What are some of the ways you’ve worked with them?
5. What were some of the challenges you faced when planning this project? How were they
overcome? (PROBE: internal to organization, external, resource-based) 
6. For those of you who don’t normally focus on hepatitis B, what are some ways that you’ve
incorporated this project work with your organization’s mission? How has it gone? 
2 Implementation of Current Project  
1. What has been your organization’s role in the project?
2. What were the steps you used to help implement or start the project?
3. What have been some of the main project activities you’ve participated in?
– How did they go?
– Were there things you’d do differently? If so, what?
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4. How did your organization’s role in the project change over time?
– Why did your organization’s role change?
5. What were your organization’s greatest successes during this project?
– To what or whom do you attribute these successes?
6. More globally, what were the project’s greatest successes? To what or whom do you attribute
these successes? 
7. What were some of the barriers or challenges you faced working on this project?
– How were they addressed?
– Who was responsible for addressing them?
3 Stakeholder Committee 
1. How did you get involved in the stakeholder committee?
2. What have been the most important roles of the stakeholder committee during the project?
3. Describe for me how the stakeholder committee has benefitted this project.
4. What were some of the challenges encountered by the stakeholder committee? How were the
challenges addressed? 
5. What do you think about the monthly stakeholder committee meetings? (PROBE: frequency,
subject matter, participation levels, etc.) 
6. How has the stakeholder committee changed over time?
7. Is there anything you wished was different about the stakeholder committee?
4 Sustainability 
1. If the stakeholder committee were to continue after the CDC contract ends, would you continue
to be involved? Why or why not? 
2. To what extent do you think this work is sustainable after the CDC contract ends? What
resources are critical to sustainability? 
5 Conclusion 
1. What would you tell other jurisdictions that are considering developing a similar project?
– Would you suggest to them that they form a stakeholder committee? Why or why not?
2. Is there anything else you would like to say about any of the topics we’ve discussed or about
your experiences?  
I would like to thank you for your time and opinions today. Your feedback was very useful and will 
be very helpful. 
Updated 6-5-2013 
Hepatitis B Foundation 
Codebook for HBV screening data 
**Dataset rule ‐ non‐response on screening form = blank cell in dataset 
Venue Codes: 
1 = "Public clinic" 
2 = "Private clinic" 
3 = "Hospital" 
4 = "Community center" 
5 = "Church" 
6 = "health fair" 
7= “festival or cultural event” 
8= “corporation/business” 
9= “restaurant” 
10= “pharmacy” 
________________________________________________________________________ 
Column A: “Unique Participant ID” 
Code rule = starting with “1” for first participant 
Column B: “Age” 
Column C: “Gender” 
1 = Male 
2 = Female 
Column D: “English your primary language” 
 1 = Yes 
 2 = No 
Column E‐F (For multi‐ethnic participants): “Race/Ethnicity” 
1 = Black 
2 = White 
3 = Hispanic 
4 = Asian/Pacific Islander 
5 = Native American/Alaska Native 
6 = Other 
Column G: “In what country were you born?” 
1=Korea 
2=China 
3=India 
4=U.S. 
5=Indonesia 
6=Vietnam 
Appendix G
Updated 6-5-2013 
7=Mexico 
8=Lao   
9=Cambodia 
10=Africa 
11=Malaysia 
12=Hong Kong 
13=Germany 
14=Bolivia 
15=Jamaica 
16=Burma 
17=Puerto Rico 
18=Canada 
19=Thailand 
20=Scotland 
21=Haiti 
22=Sierra Leone 
23=United Kingdom 
24= Ghana 
25= Nigeria 
26= Benin 
27= Mauritania 
28= Guinea 
29= Senegal 
  30= Ivory Coast  
  31= Mali 
  32= Taïr  
  33= Burkina Faso 
  34= Gambia 
  35= Niger 
  36= Congo 
  37= Liberia 
  38= Philippines  
  39= Colombia  
  40= Taiwan 
  41= Shanghai  
42=Dominican Republic 
43=Austria 
44=Russia 
45=Japan 
46=Bhutan 
47‐Italy 
48=Singapore 
49=Bangkok 
 
Column H: “What year did you arrive in the United States?” 
4 digit year 
Updated 6-5-2013 
 
Column I: “What was your mother’s country of birth?” 
  Same codes as above   
 
Column J: “What was your father’s country of birth?” 
  Same codes as above 
 
Column K: “Pregnant”  
code rule = leave blank for male gender (column C=1) 
1 = Yes 
       2 = No 
       3 = Don't Know 
 
Column L: “Highest education level” 
  1 = Less than high school 
       2 = High school diploma or GED 
       3 = Technical/vocational training 
      4 = Some college 
       5 = College degree 
       6 = Graduate degree 
    
Column M‐R (Multiple Reasons): “Why are you here for testing? 
Code rule = responses “8” or higher fall into “other” category 
Code rule for response “was not vaccinated as an infant (if U.S. born)” = 8:88 
       1 = My doctor recommended I come in for testing 
       2 = My insurance won't cover testing and I want to be tested 
       3 = I think I might be infected with hepatitis B 
       4 = A family member or personal contact is infected with hepatitis B 
       5 = I saw/heard an ad for it 
      6 = My family member recommended I come in 
       7 = I was here or at an event and someone recruited me 
      8 = Received personal letter from CBO or Clinic 
  9= my employer made testing available 
  10 = Wanted to get screened  
  11 = Friend recommended it to me  
  12 = Wanted to get vaccinated  
13 = wanted to check antibody status 
14 = I want to be healthy 
15= I do not have insurance 
 
Column S: “Do you currently have any family members with Hepatitis B?” 
       1 = Yes 
       2 = No 
       3 = Don't Know 
 
Column T‐V (for multiple responses): “If Yes, Who”: 
Updated 6-5-2013 
Code rule = enter only if response for column R=1 (yes) 
Code rule = responses “9” or higher fall into “other” category 
  1= spouse 
  2= mother 
  3= father 
  4= sibling 
  5= child 
  6= cousin 
  7= grandparent 
  8= aunt/uncle 
  9= nephew/niece 
10=great uncle/great aunt 
 
Column W: “Do you currently have any family members with HCC?” 
       1 = Yes 
       2 = No 
       3 = Don't Know 
 
Column X,Y: “If Yes, Who”: 
Code rule = enter only if response for column V=1 (yes) 
Code rule = responses “9” or higher fall into “other” category 
  1= spouse 
  2= mother 
  3= father 
  4= sibling 
  5= child 
  6= cousin 
  7= grandparent 
  8= aunt/uncle 
  9= nephew/niece 
10=great uncle/great aunt 
 
Column Z: “How many people do you live with?”      
  2 digits 
 
Column AA: “Are you living with anyone with Hepatitis B?” 
1 = Yes 
       2 = No 
  3 = Don’t Know 
      
Column AB: “Have you ever had your blood tested for hepatitis B?” 
       1 = Yes 
      2 = No 
      3 = Don't Know 
      
Column AC: “If yes, what was the outcome of the test?” 
Updated 6-5-2013 
1 = Positive 
2 = Negative 
3 = Don't Know 
Column AD: “Were you ever given medicine to treat your hepatitis?” 
1 = Yes 
2 = No 
3 = Don't Know 
Column AE: “Have you ever received vaccinations or shots to protect you from hepatitis 
B?” 
1 = Yes 
2 = No 
3 = Don't Know 
Column AF: “Do you currently have health insurance?” 
1 = Yes 
2 = No 
3 = Don't Know 
Column AG: “Do you currently have a regular doctor or health care provider?” 
1 = Yes 
2 = No 
3 = Don't Know 
Column AH: “At the end of this screening, if you test positive, do you intent to seek 
treatment within the next 6 months?” 
1= Yes 
2= I’d like to, but I cannot pay for treatment if I’m positive 
3= No, I don’t want to be treated right now for non‐financial reasons 
Column AI: “have you seen a doctor within the past 12 months? 
1 = Yes 
2 = No 
Column AJ:  “Type of venue” 
1 = Public clinic 
2 = Private clinic 
3 = Hospital 
4 = Community center 
5 = Church 
6 = health fair 
7= festival or cultural event 
Column AK: Screening Date 
Updated 6-5-2013 
Column AL: "HBsAg test result” 
1 = HBsAg positive 
2 = HBsAg negative 
3 = inconclusive 
Column AM: “Anti‐HBs test result” 
1 = Anti‐HBs positive 
2 = Anti‐HBS negative 
3 = inconclusive 
Column AN: “Referred” (referred for care and/or treatment) 
Code rule = enter only if person is HBsAg+/HBsAb‐  
1=Yes 
2=No 
3=Unreachable (loss to follow‐up) 
4=Not yet time to call 
Column AO: “Appointment” (has made an appointment with a clinician) 
Code rule = enter only if person is HBsAg+/HBsAb‐  
1=Yes 
2=No 
3=Unreachable (loss to follow‐up) 
4=Not yet time to call 
Column AP: “Received” (has completed their first appointment with a clinician at 3 
month follow‐up) 
Code rule = enter only if person is HBsAg+/HBsAb‐  
1=Yes 
2=No 
3=Unreachable (loss to follow‐up) 
4=Not yet time to call 
Column AQ: “RefVacc” (referred for vaccine) 
Code rule = enter only if person is HBsAg‐/HBsAb‐ 
1=Yes 
2=No 
3=Unreachable (loss to follow‐up) 
4=Not yet time to call 
